Video

Dependent Care Expansion Boosts Survival in AYA Patients With Cancer

Author(s):

Research showed a survival improvement in adolescent and young adult cancer survival after the Dependent Care Expansion allowed patients to be on their parents’ insurance until the age of 26.

Adolescent and young adult (AYA) patients with cancer tend to have the largest proportion of individuals who are uninsured, though the Affordable Care Act’s Dependent Care Expansion (DCE) is help bridging that gap — and may even lead to improved outcomes, explained Dr. Susan Parsons, medical director of the Reid R. Sacco AYA Cancer Program at Tufts Medical Center in Boston and professor of medicine and pediatrics at Tufts University School of Medicine.

The DCE allows eligible young adults to stay on their parents’ insurance plan until the age of 26. Parsons cited recent research published in the journal The Oncologist showing two-year survival significantly improved for patients between the ages of 19 and 23 after the DEC was passed.

“So that was a huge impact to get them insured, but to see that translate to better cancer outcomes was really impressive,” Parsons said.

READ MORE:The ‘Toxicity of Cancer’ Includes Lifetime Economic, Non-Financial Costs in AYAs

Transcript

I think that there are a couple of federal programs that parents may need to be aware of, particularly for young adults, and that I think the one that is the most impactful in terms of impact on survival is the Dependent Care Expansion (DCE) under the Affordable Care Act.

DCE allowed patients to remain on their parents’ health insurance until the age of 26, which was hugely impactful. And I was at a conference last week and (Dr. Michael) Roth from (The University of Texas) MD Anderson (Cancer Center) showed some incredible slides that that patients who were insured under the DCE actually had better survival. … That was incredible to me. I mean, I had long been aware of that provision, I was very happy about that, because AYAs historically had the largest proportion of uninsured among any cancer group. So that was a huge impact to get them insured, but to see that translate to better cancer outcomes was really impressive.

So, parents need to know about that so that they don't make the mistake of dropping their child's coverage for that very vulnerable period of transition from late adolescence to early young adulthood which is fraught with all sorts of important transitions.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Related Content